The Expression of Circulating miR-497 and Metadherin in Hepatocellular Carcinoma: Relation to the Tumor Characteristics and Patients' Survival

A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma

Background

Recently, microRNA-497 (miR-497) has been reported as a prognostic marker for hepatocellular carcinoma (HCC). However, there is no systematic study summarizing these data. Herein, we elucidated the prognostic role of miR497 in HCC by using meta-analysis.

Methods

We systematically searched Embase, PubMed, Web of Science, and, China National Knowledge Infrastructure for relevant studies. The two researchers conducted data extraction and quality evaluation independently. We used hazard ratios (HRs), odds ratios (ORs), and their 95% confidence interval (95% CI) to evaluate the relationship between miR-497 expression level and HCC prognosis.

Results

A total of 6 studies involving 457 participants were included in this meta-analysis. There was a significant association between the lower level of miR-497 expression and the shorter overall survival (HR = 2.17, 95% CI: 1.67-2.84, P < 0.001). Meanwhile, patients with low miR-497 expression were more prone to vascular infiltration (OR = 2.73, 95%: 1.79-4.17, P < 0.001). However, the lower expression level of miR-497 had no significant correlation with TNM (tumor-node-metastasis) stage (OR = 1.47, 95% CI: 0.17-12.49, P=0.47).

Conclusions

MiR-497 might serve as a prognostic biomarker in HCC, but more clinical studies are needed to confirm this view.

The challenges and potential in developing microRNA associated with regeneration as biomarkers to improve prognostication for liver failure syndromes and hepatocellular carcinoma

INTRODUCTION

Determining the need for liver transplantation remains critical in the management of hepatocellular carcinoma (HCC) and liver failure syndromes (including acute liver failure and decompensated cirrhosis states). Conventional prognostic models utilize biomarkers of liver and non-liver failure and have limitations in their application. Novel biomarkers which predict regeneration may fulfil this niche. microRNA are implicated in health and disease and are present in abundance in the circulation. Despite this, they have not translated into mainstream clinical biomarkers.

AREAS COVERED

We will discuss current challenges in the prognostication of patients with liver failure syndromes as well as for patients with HCC. We will discuss biomarkers implicated with liver regeneration. We then provide an overview of the challenges in developing microRNA into clinically tractable biomarkers. Finally, we will provide a scoping review of microRNA which may have potential as prognostic biomarkers in liver failure syndromes and HCC.

EXPERT OPINION

Novel biomarkers are needed to improve prognostic models in liver failure syndromes and HCC. Biomarkers associated with liver regeneration are currently lacking and may fulfil this niche. microRNA have the potential to be developed into clinically tractable biomarkers but a consensus on standardizing methodology and reporting is required prior to large-scale studies.

Roles and Molecular Mechanisms of Biomarkers in Hepatocellular Carcinoma with Microvascular Invasion: A Review

Hepatocellular carcinoma (HCC) being a leading cause of cancer-related death, has high associated mortality and recurrence rates. It has been of great necessity and urgency to find effective HCC diagnosis and treatment measures. Studies have shown that microvascular invasion (MVI) is an independent risk factor for poor prognosis after hepatectomy. The abnormal expression of biomacromolecules such as circ-RNAs, lncRNAs, STIP1, and PD-L1 in HCC patients is strongly correlated with MVI. Deregulation of several markers mentioned in this review affects the proliferation, invasion, metastasis, EMT, and anti-apoptotic processes of HCC cells through multiple complex mechanisms. Therefore, these biomarkers may have an important clinical role and serve as promising interventional targets for HCC. In this review, we provide a comprehensive overview on the functions and regulatory mechanisms of MVI-related biomarkers in HCC.

Sanguinarine promotes apoptosis of hepatocellular carcinoma cells via regulating the miR-497-5p/CDK4 axis

OBJECTIVE

To determine the effect of sanguinarine on the biological behavior of hepatocellular carcinoma (HCC) cells via regulating the miR-497-5p/cyclin-dependent kinase 4 (CDK4) axis.

METHODS

Swiss Target Prediction was used for target prediction of sanguinarine. The targets were analyzed with KEGG enrichment analysis, and CDK4 was included in this study. Target prediction website, Diana tools enrichment analysis, and dual-luciferase reporter assay were adopted to identify the target miRNAs for CDK4. We measured expression levels of CDK4 and miR-497-5p in cancerous tissues, normal liver L02 cells, HepG2 HCC cells and sanguinarine-treated HepG2 cells. The expression of CDK4/miR-497-5p in HCC cells was intervened by treating HCC cells with sanguinarine. Cell proliferation, invasion and apoptosis were measured with CCK8, Transwell and flow cytometry, respectively.

RESULTS

CDK4 was shown to be a target for sanguinarine. Compared with L02 cells, CDK4 expression in HCC cells was significantly increased, but sanguinarine inhibited the CDK4 expression in HCC cells. The proliferation and invasion of HCC cells were inhibited, and the apoptosis was promoted by sanguinarine, but these effects were reversed by CDK4 overexpression (both P<0.05). miR-497-5p was confirmed to be a target miRNA for CDK4, and its expression was decreased in HCC cells but could be promoted by sanguinarine. The effect of miR-497-5p knockdown on HCC cells was partially reversed by si-CDK4.

CONCLUSION

Sanguinarine inhibits the proliferation and invasion of HCC cells, and induces the apoptosis of HCC cells by regulating the expression of miR-497-5p/CDK4.